---
layout: post
title: "Proposal to Refuse to Approve a New Drug Application for TRADIPITANT; Opportunity for a Hearing"
date: 2026-02-04 21:49:40 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-01027
original_published: 2025-01-16 00:00:00 +0000
significance: 8.00
---

# Proposal to Refuse to Approve a New Drug Application for TRADIPITANT; Opportunity for a Hearing

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** January 16, 2025 00:00 UTC
**Document Number:** 2025-01027

## Summary

The Director of the Center for Drug Evaluation and Research (Center Director) at the Food and Drug Administration (FDA or Agency) is proposing to refuse to approve a new drug application (NDA) submitted by Vanda Pharmaceuticals, Inc. (Vanda), for TRADIPITANT capsules, 85 milligrams (mg), in its present form. This notice summarizes the grounds for the Center Director's proposal and offers Vanda an opportunity to request a hearing on the matter.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/01/16/2025-01027/proposal-to-refuse-to-approve-a-new-drug-application-for-tradipitant-opportunity-for-a-hearing)
- API: https://www.federalregister.gov/api/v1/documents/2025-01027

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
